
Profitability, historical returns, and peer comparisons.
According to Rigel Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 96.49%. This represents a change of 292.15% compared to the average of 24.61% of the last 4 quarters.
The mean historical ROE of Rigel Pharmaceuticals, Inc. over the last ten years is 60.58%. The current 96.49% ROE has changed 59.28% with respect to the historical average. Over the past ten years (40 quarters), RIGL's ROE was at its highest in in the December 2024 quarter at 436.16%. The ROE was at its lowest in in the March 2022 quarter at -403.72%.
Average
60.58%
Median
-61.56%
Minimum
-125.79%
Maximum
531.78%
Discovering the peaks and valleys of Rigel Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 507.09%
Maximum Annual ROE = 531.78%
Minimum Annual Increase = -829.39%
Minimum Annual ROE = -125.79%
| Year | ROE | Change |
|---|---|---|
| 2025 | 93.75% | -82.37% |
| 2024 | 531.78% | 507.09% |
| 2023 | 87.60% | -79.64% |
| 2022 | 430.18% | -829.39% |
| 2021 | -58.98% | -32.53% |
| 2020 | -87.42% | -29.31% |
| 2019 | -123.66% | 92.78% |
| 2018 | -64.14% | -17.22% |
| 2017 | -77.49% | -38.39% |
| 2016 | -125.79% | 123.35% |
The current ROE of Rigel Pharmaceuticals, Inc. (RIGL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
237.71%
5-year avg
216.87%
10-year avg
60.58%
Rigel Pharmaceuticals, Inc.’s ROE is greater than Verastem, Inc. (-467.49%), less than Nurix Therapeutics, Inc. (49.34%), greater than Mereo BioPharma Group plc (-74.76%), greater than Cullinan Therapeutics, Inc. (-52.89%), less than Exelixis, Inc. (45.54%), greater than Cardiff Oncology, Inc. (-103.08%), greater than C4 Therapeutics, Inc. (-37.71%), greater than Adlai Nortye Ltd. (-21.82%), greater than ALX Oncology Holdings Inc. (-90.30%), greater than Curis, Inc. (-1035.26%),
| Company | ROE | Market cap |
|---|---|---|
| -467.49% | $857.82M | |
| 49.34% | $1.65B | |
| -74.76% | $44.91M | |
| -52.89% | $688.63M | |
| 45.54% | $17.50B | |
| -103.08% | $59.40M | |
| -37.71% | $363.66M | |
| -21.82% | $511.49M | |
| -90.30% | $159.71M | |
| -1035.26% | $1.70M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rigel Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rigel Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Rigel Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Rigel Pharmaceuticals, Inc. (RIGL)?
What is the highest ROE for Rigel Pharmaceuticals, Inc. (RIGL)?
What is the 3-year average ROE for Rigel Pharmaceuticals, Inc. (RIGL)?
What is the 5-year average ROE for Rigel Pharmaceuticals, Inc. (RIGL)?
How does the current ROE for Rigel Pharmaceuticals, Inc. (RIGL) compare to its historical average?